Gemcitabine-based therapy in pancreas cancer: Gemcitabine-docetaxel and other novel combinations

Cancer

Volumn 95, Issue 4 SUPPL., 2002, Pages 923-927

  Jacobs, Andrew D ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Docetaxel; Gemcitabine; Pancreatic cancer

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CETUXIMAB; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; IRINOTECAN; RUBITECAN; TRASTUZUMAB;

ACNE; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESPONSE; FATIGUE; FOLLICULITIS; HUMAN; LUNG DISEASE; NAUSEA AND VOMITING; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STANDARD; SURVIVAL RATE;

EID: 0037103098     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10756     Document Type: Conference Paper

References (26)

1. Cancer statistics, 2000
2. Mechanism of action of 2′, 2′-deoxycytidine triphosphate on DNA synthesis
3. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
4. Gemcitabine (G) and Taxotere (T) in patients with unresectable pancreatic carcinoma
5. A Phase I/II study of gemcitabine (G) and docetaxel (D) in patients (pts) with unresectable pancreatic cancer
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
7. Phase II study of Taxotere (docetaxel) in pancreatic adenocarcinoma
8. Docetaxel: A potentially active agent for patients with pancreatic adenocarcinoma
9. Diffuse alveolar damage in a patient treated with gemcitabine
10. Fatal pulmonary toxicity resulting from treatment with gemcitabine
11. Fatal pulmonary toxicity resulting from treatment with gemcitabine
12. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
13. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
14. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
15. Multicenter Phase II trial of first-line irinotecan and gemcitabine (Irinogem) in patients with locally advanced or metastatic pancreatic carcinoma (PC)
16. Phase I study of rubitecan and gemcitabine in patients with unresectable pancreas cancer
17. Gemcitabine and flutamide in advanced pancreatic cancer - A Phase II study
18. Effect of flutamide on survival in patients with pancreatic cancer: Results of a prospective, randomized, double blind, placebo-controlled study
19. Phase I study of a treatment with gemcitabine and docetaxel weekly in advanced pancreatic cancer
20. Final results of a Phase I study of weekly gemcitabine and docetaxel in pancreatic carcinoma and preliminary results of a Phase II study
21. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced pancreatic cancer: A multicenter Phase II study
22. Multicenter Phase II study of weekly docetaxel and gemcitabine for the treatment of patients (Pts) with advanced or recurrent pancreatic cancer
23. Pancreatic cancer: Biweekly gemcitabine/docetaxel chemotherapy
24. Docetaxel and gemcitabine in patients with advanced pancreatic cancer
25. Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer
26. Docetaxel (D) with gemcitabine (GEM) in metastatic pancreatic cancer